Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
Intra-Cellular Therapies (Nasdaq: ITCI) has announced the appointment of Sanjeev Narula as Executive Vice President and Chief Financial Officer, effective August 12, 2024. Narula, who brings extensive experience from his roles at Viatris, Pfizer, American Express, and Xerox India, will succeed Lawrence Hineline, who is retiring but will remain as a consultant to ensure a smooth transition. Dr. Sharon Mates, ITCI's Chairman and CEO, expressed excitement about Narula joining the leadership team as the company continues its rapid growth. Narula's background includes serving as CFO of Viatris and holding various financial leadership positions at Pfizer over 16 years.
Intra-Cellular Therapies (Nasdaq: ITCI) ha annunciato la nomina di Sanjeev Narula come Vicepresidente Esecutivo e Direttore Finanziario, con effetto dal 12 agosto 2024. Narula, che porta con sé un'ampia esperienza da ruoli ricoperti in Viatris, Pfizer, American Express e Xerox India, succederà a Lawrence Hineline, che si ritirerà ma rimarrà come consulente per garantire una transizione fluida. La Dott.ssa Sharon Mates, Presidente e CEO di ITCI, ha espresso entusiasmo per l'ingresso di Narula nel team di leadership mentre l'azienda continua la sua rapida crescita. Il background di Narula include il ruolo di CFO di Viatris e varie posizioni di leadership finanziaria presso Pfizer per oltre 16 anni.
Intra-Cellular Therapies (Nasdaq: ITCI) ha anunciado el nombramiento de Sanjeev Narula como Vicepresidente Ejecutivo y Director Financiero, con efecto a partir del 12 de agosto de 2024. Narula, quien aporta una amplia experiencia de sus roles en Viatris, Pfizer, American Express y Xerox India, sucederá a Lawrence Hineline, quien se retirará pero permanecerá como consultor para asegurar una transición fluida. La Dra. Sharon Mates, Presidenta y CEO de ITCI, expresó su entusiasmo por la incorporación de Narula al equipo de liderazgo mientras la empresa continúa su rápido crecimiento. La trayectoria de Narula incluye haber sido CFO de Viatris y haber ocupado varias posiciones de liderazgo financiero en Pfizer durante más de 16 años.
Intra-Cellular Therapies (Nasdaq: ITCI)는 Sanjeev Narula를 부회장 및 최고 재무 책임자로 임명했다고 발표했으며, 이는 2024년 8월 12일부터 시행됩니다. Narula는 Viatris, Pfizer, American Express 및 Xerox India에서의 경험을 가지고 있으며, 은퇴하는 Lawrence Hineline을 대신해 임명되었습니다. Hineline은 원활한 전환을 보장하기 위해 컨설턴트로 남을 것입니다. ITCI의 회장 겸 CEO인 Sharon Mates 박사는 Narula가 리더십 팀에 합류하는 것에 대해 흥분을 내비쳤으며, 회사가 빠른 성장을 이어가고 있다고 전했습니다. Narula는 Viatris의 CFO로 재직했었고, Pfizer에서 16년 이상 여러 재무 리더십 직책을 역임한 경력이 있습니다.
Intra-Cellular Therapies (Nasdaq: ITCI) a annoncé la nomination de Sanjeev Narula au poste de Vice-président exécutif et Directeur financier, effectif à partir du 12 août 2024. Narula, qui possède une vaste expérience grâce à ses rôles chez Viatris, Pfizer, American Express et Xerox India, succédera à Lawrence Hineline, qui part à la retraite mais restera consultant afin d'assurer une transition en douceur. Dr. Sharon Mates, Président et CEO d'ITCI, a exprimé son enthousiasme quant à l'arrivée de Narula dans l'équipe de direction alors que l'entreprise continue sa croissance rapide. L'expérience de Narula comprend son rôle de CFO chez Viatris et diverses positions de leadership financier chez Pfizer pendant plus de 16 ans.
Intra-Cellular Therapies (Nasdaq: ITCI) hat die Ernennung von Sanjeev Narula zum Executive Vice President und Chief Financial Officer bekannt gegeben, die ab dem 12. August 2024 wirksam wird. Narula bringt umfangreiche Erfahrungen aus seinen Tätigkeiten bei Viatris, Pfizer, American Express und Xerox Indien mit und wird Lawrence Hineline nachfolgen, der in den Ruhestand geht, aber als Berater bleibt, um einen reibungslosen Übergang sicherzustellen. Dr. Sharon Mates, Vorsitzende und CEO von ITCI, äußerte ihre Begeisterung über Narulas Eintritt in das Führungsteam, während das Unternehmen weiterhin ein schnelles Wachstum verzeichnet. Narulas Hintergrund umfasst die Tätigkeit als CFO von Viatris und verschiedene Führungspositionen im Finanzbereich bei Pfizer über 16 Jahre.
- Appointment of an experienced pharmaceutical industry finance leader as CFO
- New CFO brings extensive strategic, financial, and operational experience from large commercial stage pharmaceutical companies
- Retiring CFO will remain as a consultant to ensure a smooth transition
- None.
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sanjeev Narula will join the Company on August 12, 2024 and will serve as Executive Vice President, Chief Financial Officer. Mr. Narula will report to Dr. Sharon Mates, ITCI’s Chairman and Chief Executive Officer. Lawrence Hineline, who currently serves as Chief Financial Officer, will retire on the same date but will continue to serve as a consultant to the Company for a period of time to ensure a smooth transition.
“I am excited to welcome Mr. Narula as our Chief Financial Officer. Sanjeev’s extensive strategic, financial and operational experience in large commercial stage pharmaceutical companies make him a tremendous addition to the ITCI leadership team as the Company continues its rapid growth,” said Sharon Mates, Ph.D., Chairman and Chief Executive Officer of Intra-Cellular Therapies, Inc.
Mr. Narula joins ITCI with significant experience as a finance leader in the pharmaceutical industry. He most recently served as the Chief Financial Officer of Viatris which he joined in 2020 when the company was formed through the combination of Mylan and Upjohn, a division of Pfizer. Prior to Viatris, he served as Chief Financial Officer at Upjohn, overseeing finance, procurement and business technology for all functions of the business. Sanjeev held several other financial leadership positions during his 16 years at Pfizer, including Chief Financial Officer for its Essential Health Business and Chief Financial Officer of the Primary Care Business Unit, the largest commercial division at the time. Previously, Mr. Narula held various financial and operational leadership positions at American Express and Xerox India. Sanjeev received his bachelor’s degree in commerce (honors) from Delhi University and his Chartered Accountant degree from The Institute of Chartered Accountants of India.
“I am deeply honored to join the leadership team at Intra-Cellular Therapies as the Company’s Chief Financial Officer and look forward to contributing to ITCI’s growth strategy, as it continues to build on CAPLYTA’s commercial success and advance its exciting pipeline,” said Mr. Narula.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.
Contact:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333
Burns McClellan, Inc.
Cameron Radinovic
cradinovic@burnsmc.com
212-213-0006
FAQ
Who is the new CFO of Intra-Cellular Therapies (ITCI)?
What is Sanjeev Narula's background before joining ITCI?
When will Sanjeev Narula start his role as CFO at ITCI?
Who is Sanjeev Narula replacing as CFO at ITCI?
